P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

Authors :: G. Cohen
E. Joseph
Bruno Sangro
Shukui Qin
Zhenggang Ren
Shethah Morgan
S.L. Chan
R. Lencioni
Masatoshi Kudo
Helen Mann
Y. Arai
Source :: Annals of Oncology. 31:S202-S203
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: medicine.medical_specialty
Durvalumab
Bevacizumab
business.industry
Placebo-controlled study
Hematology
medicine.disease
Gastroenterology
Double blind
Oncology
Internal medicine
Hepatocellular carcinoma
medicine
In patient
business
medicine.drug

Tools